ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Recursos principais

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
AI Entrar Premium IconPremium Help Menu
Índice Bovespa
125.401,38
-1,36%
S&P 500
5.983,25
-0,50%
US Dollar vs BRL
5,8223
0,74%
Bitcoin
87.891,60
-3,88%
Brent Oil
74,215
-0,36%
As Melhores Corretoras Online
Registration Strip Icon for tools Aumente o nível de sua negociação com nossas ferramentas poderosas e insights em tempo real, tudo em um só lugar.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Capricor Therapeutics Inc (CAPR)

  7. Capricor Therapeutics Inc (CAPR) Notícias

CAPR

Capricor Therapeutics (CAPR)

Capricor Therapeutics Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:CAPR
DataHoraFonteTítuloCódigoCompanhia
10/02/202511:00GlobeNewswire Inc.Capricor Therapeutics to Participate in Upcoming Investor ConferencesNASDAQ:CAPRCapricor Therapeutics Inc
05/02/202519:20Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:CAPRCapricor Therapeutics Inc
06/01/202521:32Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CAPRCapricor Therapeutics Inc
02/01/202516:17Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CAPRCapricor Therapeutics Inc
02/01/202511:15GlobeNewswire Inc.Capricor Therapeutics Completes Submission of Biologics License Application to the U.S. FDA for Deramiocel for the Treatment of Duchenne Muscular DystrophyNASDAQ:CAPRCapricor Therapeutics Inc
02/12/202418:15GlobeNewswire Inc.Capricor Therapeutics to Present at Upcoming Investor ConferencesNASDAQ:CAPRCapricor Therapeutics Inc
20/11/202411:00GlobeNewswire Inc.Capricor Therapeutics Granted Orphan Drug and ATMP Status for Deramiocel by European Medicines AgencyNASDAQ:CAPRCapricor Therapeutics Inc
14/11/202418:30Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:CAPRCapricor Therapeutics Inc
13/11/202418:01GlobeNewswire Inc.Capricor Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate UpdateNASDAQ:CAPRCapricor Therapeutics Inc
12/11/202413:46Edgar (US Regulatory)Form SC 13G - Statement of Beneficial Ownership by Certain InvestorsNASDAQ:CAPRCapricor Therapeutics Inc
12/11/202411:00GlobeNewswire Inc.Capricor Therapeutics to Present Exosome Platform Updates at 2024 American Association of Extracellular Vesicles Annual MeetingNASDAQ:CAPRCapricor Therapeutics Inc
12/11/202402:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:CAPRCapricor Therapeutics Inc
05/11/202411:00GlobeNewswire Inc.Capricor Therapeutics to Present Third Quarter 2024 Financial Results and Recent Corporate Update on November 13NASDAQ:CAPRCapricor Therapeutics Inc
22/10/202418:11Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:CAPRCapricor Therapeutics Inc
18/10/202417:01GlobeNewswire Inc.Capricor Therapeutics Announces Closing of Underwritten Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional SharesNASDAQ:CAPRCapricor Therapeutics Inc
17/10/202417:15Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:CAPRCapricor Therapeutics Inc
17/10/202407:00GlobeNewswire Inc.Capricor Therapeutics Announces Pricing of Approximately $75 Million Public Offering of Common StockNASDAQ:CAPRCapricor Therapeutics Inc
16/10/202417:17GlobeNewswire Inc.Capricor Therapeutics Announces Proposed Public Offering of Common StockNASDAQ:CAPRCapricor Therapeutics Inc
16/10/202414:31Edgar (US Regulatory)Form S-3/A - Registration statement under Securities Act of 1933: [Amend]NASDAQ:CAPRCapricor Therapeutics Inc
11/10/202410:15GlobeNewswire Inc.Capricor Therapeutics Announces Positive Long-Term Data from HOPE-2 OLE Study in Duchenne Muscular Dystrophy at 2024 World Muscle Society CongressNASDAQ:CAPRCapricor Therapeutics Inc
09/10/202410:15GlobeNewswire Inc.Capricor Therapeutics Announces Initiation of Rolling Submission of Biologics License Application (BLA) with U.S. FDA for Deramiocel for the Treatment of Duchenne Muscular DystrophyNASDAQ:CAPRCapricor Therapeutics Inc
04/10/202410:15GlobeNewswire Inc.Capricor Therapeutics to Present Long-Term Data from HOPE-2 Open Label Extension Study at 2024 World Muscle Society CongressNASDAQ:CAPRCapricor Therapeutics Inc
24/09/202417:03Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:CAPRCapricor Therapeutics Inc
24/09/202409:00GlobeNewswire Inc.Capricor Therapeutics Announces Intent to File Biologics License Application for Full Approval of Deramiocel for the Treatment of Duchenne Muscular Dystrophy CardiomyopathyNASDAQ:CAPRCapricor Therapeutics Inc
23/09/202410:25GlobeNewswire Inc.Capricor Therapeutics to Provide Duchenne Muscular Dystrophy Program Update on September 24, 2024NASDAQ:CAPRCapricor Therapeutics Inc
17/09/202410:15GlobeNewswire Inc.Capricor Therapeutics Signs Binding Term Sheet with Nippon Shinyaku for European Expansion and Commercialization of Deramiocel for the Treatment of Duchenne Muscular DystrophyNASDAQ:CAPRCapricor Therapeutics Inc
06/09/202409:30GlobeNewswire Inc.Capricor Therapeutics to Present at Upcoming Investor and Scientific ConferencesNASDAQ:CAPRCapricor Therapeutics Inc
23/08/202417:02Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:CAPRCapricor Therapeutics Inc
07/08/202417:05GlobeNewswire Inc.Capricor Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate UpdateNASDAQ:CAPRCapricor Therapeutics Inc
31/07/202410:00GlobeNewswire Inc.Capricor Therapeutics to Present Second Quarter 2024 Financial Results and Recent Corporate Update on August 7NASDAQ:CAPRCapricor Therapeutics Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:CAPR

Seu Histórico Recente

BOV
IBOV
Índice Bovespa
BOV
PRIO3
PETRORIO ON
BOV
TPIS3
TRIUNFO PART ON
BOV
CMIG4
CEMIG PN
BOV
ONCO3
Oncoclinicas Brasil Serv... ON
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2025 ADVFN PLC - Todos os direitos reservados

Vá sem anúncios

Assine uma experiência sem anúncios

Sem anúncios

Experimente agora

Manter os anúncios